Patient characteristics
| Characteristic | |
|---|---|
| Age (mean) (range) (yr) | 55.7 (30–86) |
| Sex | M/F = 10:10 |
| Follow-up period (mean) (range) (mo) | 20.4 (1–62) |
| Clinical stage (No.) | |
| ≤II | 0 |
| III | 3 |
| IV | 17 |
| CTCAE grade (No.) | |
| 0–2 | 0 |
| 3 | 20 |
| 4, 5 | 0 |
| ICIs (No.) | |
| Ipilimumab + nivolumab | 11 |
| Ipilimumab | 9 |
| Main physical symptoms (No.) | |
| Headache | 13 |
| Fatigue/malaise | 3 |
| Nausea/vomiting | 2 |
| Edema | 1 |
| Numbness | 1 |
| Loss of vision/visual field disorder | 0 |
| Diabetes insipidus | 0 |
| No symptom | 0 |